Vera Therapeutics, Inc. is a pharmaceutical company based in the United States that specializes in developing innovative treatments for patients with serious immunological diseases. They are currently in the clinical stage and their focus is on a product candidate called atacicept, which is a fusion protein that blocks substances stimulating B cells to produce autoantibodies. With an ESG score of 26.5, Vera Therapeutics is considered a medium risk investment.